Show simple item record

dc.contributor.authorLópez-Perea, Noemí 
dc.contributor.authorMasa-Calles, Josefa 
dc.contributor.authorTorres-de Mier, Maria Viarce 
dc.contributor.authorFernández-García, Aurora 
dc.contributor.authorEchevarria, Juan Emilio 
dc.contributor.authorOry, Fernando de 
dc.contributor.authorMartinez de Aragon-Esquivias, Maria Victoria 
dc.date.accessioned2020-05-18T10:07:54Z
dc.date.available2020-05-18T10:07:54Z
dc.date.issued2017
dc.identifier.citationVaccine. 2017 Aug 3;35(34):4339-4345.es_ES
dc.identifier.issn0264-410Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10154
dc.description.abstractThe mumps vaccine (Jeryl-Lynn-strain) was introduced in Spain in 1981, and a vaccination policy which included a second dose was added in 1995. From 1992-1999, a Rubini-strain based vaccine was administered in many regions but later withdrawn due to lack of effectiveness. Despite high levels of vaccination coverage, epidemics have continued to appear. We characterized the three epidemic waves of mumps between 1998 and 2014, identifying major changes in susceptible populations using Poisson regression. For the period 1998-2003 (P1), the most affected group was from 1 to 4years old (y) [Incidence Rate (IR)=71.7 cases/100,000 population]; in the periods 2004-2009 (P2) and 2010-2014 (P3) IR ratio (IRR) increased among 15-24y (P2=1.46; P3=2.68) and 25-34y (P2=2.17; P3=4.05). Hospitalization rate (HR), complication rate (CR) and neurological complication rate (NR) among hospitalized subjects decreased across the epidemics, except for 25-34y which increased: HR ratio (HRR) (P2=2.18; P3=2.16), CRR (P3=2.48), NRR (P3=2.41). In Spain mumps incidence increased, while an overall decrease of hospitalizations and severe complications occurred across the epidemics. Cohorts born during periods of low vaccination coverage and those vaccinated with Rubini-strain were the most affected populations, leading to a shift in mumps cases from children to adolescents and young adults; this also reveals the waning immunity provided by the mumps vaccine. Despite not preventing all mumps cases, the vaccine appears to prevent serious forms of the disease.es_ES
dc.description.sponsorshipThis study was funded in part by Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (PI12/02006) and by Acción Estratégica de Salud, Instituto de Salud Carlos III (PI15CIII/00023).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEpidemiological surveillancees_ES
dc.subjectImmunization programses_ES
dc.subjectMumpses_ES
dc.subjectSevere complicationses_ES
dc.subjectSpaines_ES
dc.subjectVaccinationes_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAge Factors es_ES
dc.subject.meshAged es_ES
dc.subject.meshChild es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshDisease Outbreaks es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHospitalization es_ES
dc.subject.meshHumans es_ES
dc.subject.meshIncidence es_ES
dc.subject.meshInfant es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshMumps es_ES
dc.subject.meshSpain es_ES
dc.subject.meshVaccination es_ES
dc.subject.meshVaccination Coverage es_ES
dc.subject.meshYoung Adult es_ES
dc.subject.meshEpidemiological Monitoring es_ES
dc.subject.meshImmunization Programs es_ES
dc.subject.meshMumps Vaccine es_ES
dc.titleShift within age-groups of mumps incidence, hospitalizations and severe complications in a highly vaccinated population. Spain, 1998-2014es_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID28687402es_ES
dc.format.volume35es_ES
dc.format.number34es_ES
dc.format.page4339-4345es_ES
dc.identifier.doi10.1016/j.vaccine.2017.06.075es_ES
dc.contributor.funderFondo de Investigaciones Sanitariases_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.identifier.e-issn1873-2518es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.vaccine.2017.06.075es_ES
dc.identifier.journalVaccinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI12/02006es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/es_ES
dc.relation.projectIDPI15CIII/00023es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional